
Quantum Computing Advantage in Drug Discovery

*Prepared by the National Quantum Algorithm Center (NQAC)
at the Illinois Quantum & Microelectronics Park (IQMP)*

Introduction

Quantum computing introduces a fundamentally different computational model from classical computing [1], with emerging use cases in quantum simulation, optimization, machine learning, and security. This Industry Brief focuses on a subset of potential use cases for quantum computing in drug discovery and related life sciences fields.

Drug discovery is expensive, slow, and constrained by the computational effort required to represent complex molecular systems [2]. Because classical methods must approximate inherently quantum phenomena, many discovery bottlenecks stem from a mismatch between the problems and the tools used to solve them. Quantum computing is directly aligned with these challenges and offers the potential for step-change improvements in accuracy, speed, and search capability—advantages that early adopters will be best positioned to capture.

Why Drug Discovery Pushes the Limits of Classical Computing

Classical approaches struggle because they approximate quantum systems and must simplify the molecular and biological complexity at the heart of drug discovery [1][2]. As molecular size and dimensionality grow, computational cost rises exponentially, making many problems effectively intractable on classical hardware [1][3]. Key tasks illustrate these limits: accurate binding prediction depends on electron-level interactions that are infeasible to model beyond small molecules [1][3][4][5]; lead optimization must navigate an immense chemical space of roughly 10^{60} candidates [1][3]; and systems biology and ADMET (absorption, distribution, metabolism, excretion, and toxicity) modeling requires multi-scale simulations that exceed current computational capacity [3]. Ultimately, these challenges arise because chemistry and biology obey quantum mechanics, while today's computational tools do not.

Quantum Advantage in Drug Discovery

Quantum computing is well suited to molecular science because it operates according to the same quantum mechanical principles that govern electron behavior, chemical bonding, and reaction dynamics [1][3]. Unlike classical computers, which rely on approximations to represent quantum states, quantum systems can in principle encode these states directly and capture interactions that classical methods must simplify [1]. This alignment positions quantum computing to address several high-value bottlenecks in drug discovery where classical scaling limits are most severe.

High-Impact Areas Where Advantage May Emerge

Quantum Simulation

- **Molecular interaction modeling and binding prediction:** Quantum simulations could compute binding energies and reaction pathways with chemical accuracy, reducing reliance on classical heuristics [1][4][5]. Early advantage is expected for small and medium-size molecular systems where accuracy is critical and classical costs grow quickly [5].
- **Molecular systems modeling and pathway analysis:** Quantum simulation can reveal quantum-driven phenomena such as tunneling and electron transfer that classical models often oversimplify [1][6]. Capturing these effects supports deeper insights into biological mechanisms and strengthens target validation [1][6].
- **ADMET and toxicity prediction:** More accurate modeling of molecular transformations and metabolic pathways could improve safety predictions by adding mechanistic detail to ADMET workflows [1][2][3]. Hybrid quantum–classical methods may also help bridge molecular-scale insights with system-level behavior [1][3].

Quantum Optimization

- **Lead discovery and optimization:** Quantum-enhanced optimization algorithms may enable more efficient searches across vast chemical spaces and support balancing multiple design criteria during lead refinement [2][3]. This could open access to novel scaffolds beyond existing datasets and known chemical series [1][2].

As quantum hardware improves, quantum methods are expected to pull ahead because many quantum chemistry problems that scale exponentially on classical computers theoretically scale only polynomially on quantum architectures [1][3][4]. Progress in hybrid algorithms, error mitigation, and specialized hardware for chemistry continues to accelerate this trajectory [1][2][7]. In the near term, quantum-inspired and hybrid approaches will complement classical HPC and modern AI models rather than replace them, forming a transitional path toward full quantum advantage [1][2][4][7]. While these advances are promising, achieving large-scale chemical accuracy will likely require fault-tolerant quantum computers. Current devices depend on techniques to adjust for computational noise, so early applications will focus on smaller systems and hybrid workflows where noise can be managed effectively [1][4][5].

A Grand Challenge for Quantum Computing in Drug Discovery

As part of this Industry Brief Series, we have identified Grand Challenges relevant for different industries. By articulating these challenges, we hope to set a long-term direction for exploring quantum approaches and a clearer understanding of where future breakthroughs would translate into meaningful impact for various industries.

Quantum-Accurate Molecular Property Prediction from First-Principles Physics

Achieving quantum-accurate molecular property prediction from first principles represents the unifying challenge at the heart of quantum computing's potential in drug discovery. The limitations of classical computing outlined earlier all point toward this central goal: reliably simulating complex interactions such as non-covalent binding, transition-metal chemistry, cryptic pockets, and tautomeric shifts—phenomena that current methods can only approximate. Solving this would enable far more confident in-silico assessments of drug–target interactions and provide deeper insight into the mechanisms that drive efficacy and metabolism. Importantly, the ability to predict these outcomes with higher fidelity could materially reduce late-stage failures, shorten development timelines, and concentrate investment on candidates with the highest likelihood of success. By articulating this challenge clearly, organizations gain a long-term direction for exploring quantum approaches and a more accurate understanding of where breakthroughs would translate into meaningful R&D impact.

Why Executives Should Act Now

The organizations that engage early in quantum computing will secure advantages in access to key resources such as talent, hardware, and know-how that fast followers cannot easily replicate [8][9]. Access to these key resources is already limited and is concentrating around first movers [6][8]. Industry leaders across pharma and adjacent sectors are piloting quantum collaborations, signaling that the competitive landscape is shifting [6][9]. Executives who invest now in partnerships, internal capability, and focused exploratory use cases will be better positioned for the inflection point where quantum advantage begins to materialize [6][9].

How Executives Can Get Started

- Identify discovery, modeling, or optimization processes that are currently constrained by computational limits
- Form cross-functional teams to assess quantum-relevant pain points and potential pilot opportunities
- Partner with the Illinois Quantum & Microelectronics Park to connect with quantum vendors, researchers, and technical advisors
- Launch small, well-scoped proof-of-concept projects to build internal familiarity and technical readiness
- Promote awareness across R&D and strategy teams about how quantum workflows may integrate with existing AI and HPC pipelines

Sources

1. Santagati et al., “Drug design on quantum computers,” *Nature Physics* (2024), arXiv:2301.04114.
2. Zhou et al., “Quantum-machine-assisted Drug Discovery,” *npj Drug Discovery*, volume 3, Article number: 1 (2026), arXiv:2408.13479.
3. Cao et al., “Potential of quantum computing for drug discovery,” *IBM Journal of Research and Development*, 2018.
4. von Burg et al., “A Perspective on Quantum Computing Applications in Quantum Chemistry using 25–100 Logical Qubits,” arXiv:2506.19337v2, 2025.
5. Otten et al., “Quantum Resources Required for Binding Affinity Calculations of Amyloid Beta,” arXiv:2406.18744, 2024.
6. McKinsey & Company, “The quantum revolution in pharma: Faster, smarter, and more precise,” 2025.
7. Basu et al., “Towards quantum-enabled cell-centric therapeutics,” arXiv:2307.05734.
8. BCG, “Quantum Computing Is Becoming Business Ready,” 2023.
9. BCG, “The Path to Quantum Advantage,” 2021.